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Introduction
Type I interferons comprise a large group of structurally 
similar cytokines that includes 13 subtypes of IFNα and 
unique IFNβ, IFNε, IFNκ and IFNω in humans, which 
exert similar but not identical eﬀ   ects due to their 
diﬀ  erent binding aﬃ   nities to a common cognate receptor 
[1,2]. Genes coding for the type I interferons are clustered 
on human chromosome 9p22 and apparently originated 
from a duplication of a single gene [3]. Both the number 
of genes and their intronless structure point to the vital 
role of interferons in host defence against viruses. During 
a viral infection, type I interferons activate innate immune 
responses and exert anti-proliferative and cytotoxic 
eﬀ  ects on cells. Type I interferons also induce survival, 
maturation and activation of diﬀ  erent subsets of dendritic 
cells, thereby enhancing their antigen-presenting abilities. 
Activated dendritic cells upregulate expression of human 
leucocyte antigen and other co-stimulatory molecules, 
such as CD40, CD80, CD83 and CD86 [4-6], and initiate 
the production of cytokines such as TNFα, IL-6, IL-10, 
IL-12, IL-15, IL-18, IL-23 [7-10], B-cell activating factor 
[11,12], and the chemokines CCL3, CCL4, CCL5, and 
CXCL10 [13-17], which in turn exert co-stimulatory 
eﬀ  ects on all other immune cells.
Type I interferons link together both innate and adap-
tive immune systems. Th  eir  eﬀ  ects in adaptive immunity 
are mediated through activated dendritic cells and also 
by direct binding to interferon receptors on B cells, 
T cells, neutrophils and natural killer (NK) cells. Th  ey 
promote immunoglobulin class switching and antibody 
production in B cells, promote T-cell eﬀ  ector activity and 
promote synthesis of IFNγ by T cells and NK cells, and 
they protect both B cells and T cells from apoptosis 
[18-32].
Type I interferons can also promote pathologic auto-
immunity; IFNα is able to break self-tolerance by 
activating antigen-presenting cells after uptake of self 
material [33]. Th  e ﬁ   rst genetic link between type I 
interferons and autoimmune diseases was provided by 
the observation of an elevated IFNα level in the sera of 
patients with systemic lupus erythematosus (SLE), and 
the familial aggregation of this trait in healthy relatives 
[34-37]. Th   is observation suggested that the alteration of 
the interferon pathway is a primary event in SLE patho-
genesis, rather than a consequence of the disease pheno-
type. Th   e levels of IFNα activity in patients with SLE are 
positively correlated with both clinical and serological 
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Type I interferons play an outstanding role in innate 
and adaptive immunity by enhancing functions of 
dendritic cells, inducing diff  erentiation of monocytes, 
promoting immunoglobulin class switching in B 
cells and stimulating eff  ector functions of T cells. The 
increased production of IFNα/β by plasmacytoid 
dendritic cells could be responsible for not only 
effi   cient antiviral defence, but it also may be a 
pathological factor in the development of various 
autoimmune disorders. The fi  rst evidence of a genetic 
link between type I interferons and autoimmune 
diseases was the observation that elevated IFNα 
activity is frequently detected in the sera of patients 
with systemic lupus erythematosus, and that this trait 
shows high heritability and familial aggregation in 
their fi  rst-degree healthy relatives. To date, a number 
of genes involved in interferon signalling have been 
associated with various autoimmune diseases. 
Patients with systemic lupus erythematosus, Sjögren’s 
syndrome, dermatomyositis, psoriasis, and a fraction 
of patients with rheumatoid arthritis display a specifi  c 
expression pattern of interferon-dependent genes 
in their leukocytes, termed the interferon signature. 
Here, in an attempt to understand the role of type 
I interferons in the pathogenesis of autoimmunity, 
we review the recent advances in the genetics of 
autoimmune diseases focusing on the association of 
genes involved in type I interferon pathways.
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© 2010 BioMed Central Ltdmarkers of disease activity [34,35,37,38]. Increased levels 
of IFNα were also observed in patients with rheumatoid 
arthritis (RA), scleroderma and primary Sjögren’s 
syndrome (pSS) [34]. Moreover, about 20% of patients 
with long-term treatment of haematological malignancies 
and viral hepatitis infections with recombinant IFNα 
develop lupus or other autoimmune diseases, such as 
type 1 diabetes, psoriasis, inﬂ  ammatory arthritis and pSS, 
or show symptoms resembling autoimmune diseases 
[39,40]. Th  ese results together further substantiate the 
involve  ment of IFNα in the development of various 
autoimmune disorders.
SLE patients display another important feature of an 
active interferon-mediated signalling: an overexpression 
of genes regulated by type I interferon, termed the 
interferon signature, which is more prominent in patients 
with severe disease [41]. In agreement with the idea of a 
shared genetic basis of autoimmune diseases [42], the 
interferon signature has also been demonstrated for pSS, 
dermatomyositis, psoriasis and some RA patients [43].
In the present review we will give a brief overview of 
the type I interferon signalling, with the main focus on 
the genetic linkage between type I interferon-mediated 
pathways and autoimmune diseases. True functional 
variants for the majority of associated genes have not yet 
been found, and for that reason the biology behind them 
is largely unknown. Owing to the space constraints, we 
shall examine in detail only a few genes with either strong 
or consistent evidence of association with autoimmune 
diseases for which functional variants have been 
described or, at least, proposed. A more complete list of 
associated genes involved in interferon-related pathways 
is presented in Table 1.
Genetic linkages to the pathways inducing 
production of type I interferons
Although all nucleated cells can produce type I inter-
ferons in response to viral infections, there is a group of 
professional cells producing extremely high amounts: the 
plasmacytoid dendritic cells (pDCs) [44,45]. Th  e bulk 
yield of interferons may reach 3 to 10 pg/cell, which is 
estimated to be about 1,000 times more than in cells of 
any other type. Th   e ability of cells to sense infections is 
linked to the special sensors localized on the membrane 
and in the cytosol (Figure 1). Th  e  ﬁ  rst group consists of 
the Toll-like receptors (TLRs), of which TLR3, TLR4, 
TLR7/8 and TLR9 transmit the signal resulting in the 
induction of interferon genes after ligation with dsRNA, 
bacterial lipopolysaccharides, single-stranded RNA 
and unmethylated CpG-rich DNA, respectively [46]. 
Unlike cells of other types, pDCs express only TLR7 
and TLR9, giving these two receptors a paramount 
importance in type I inter  feron production [47-51]. 
Another group of ubiquitous sensors, the RNA helicases 
retinoic acid-inducible gene 1 and melanoma diﬀ  er-
entiation-associated gene 5, reside in the cytoplasm and 
recognize dsRNA and viral replicat  ing intermediates 
[52,53]. Th   e presence of viral RNA in the cytoplasm may 
activate the ultimate weapons of the antiviral defence – 
dsRNA-dependent serine–threonine kinase [54] and 
2´,5´-oligoadenylate synthetase [55] – resulting in com-
plete stalling of the cellular transcription and translation 
in the infected cell and, eventually, apoptosis. It was 
shown recently that cytoplasmic dsDNA could be recog-
nized by two cytosolic dsDNA sensors: DNA-dependent 
activator of interferon regula  tory factors (IRFs), and 
absent in melanoma 2 – both signal through TBK1 and 
IRF3, and induce genes for IFNβ and proinﬂ  ammatory 
cytokines [56]. Th   e binding of absent in melanoma 2 to 
dsDNA leads to activation of caspase 1 and caspase 3, 
which cleaves and releases IL-1β and IL-18 [57-61].
Interestingly, autophagy – an autonomous process of 
re-utilization of cellular organelles – has been also 
implicated in the induction of innate immune responses 
and production of type I interferons [62]. Viral RNA could 
be engulfed by a forming autophagosome and, after fusing 
it with an endosome, could be detected by TLR7. Mouse 
pDCs lacking the autophagy-related 5 (yeast) (Atg5) gene 
showed a decreased IFNα response and were unable to 
respond to vesicular stomatitis virus infection [62].
It is important to note that the activation of a particular 
pathway depends upon the cell type, the nature of the 
pathogen and the cytokines present in the milieu. All of 
these factors determine the pattern of induced genes, 
which could vary from the induction of IFNα/β genes in 
pDCs in response to certain viral infections to the 
induction of genes for other proinﬂ  ammatory cytokines 
in another cell type.
Transcription factors at the knots of the signalling cascades
IRF5 belongs to the family of IRFs and plays an essential 
role in many aspects of cellular responses to interferons, 
including antiviral defence, cell growth regulation and 
apoptosis [63-67]. Th  e IRF5 gene was associated ﬁ  rst 
with SLE [68,69], and since then its association has been 
established with many other autoimmune diseases, 
including RA [70], Sjögren’s syndrome [71], inﬂ  ammatory 
bowel disease [72], and multiple sclerosis [73]. Th  e  genetics 
of IRF5 is very well studied to date, and ﬁ  nds support in 
the functional analysis of the associated causative 
variants. Several functional polymorphisms are believed 
to play a major role in determining the gene function in 
the pathogenesis, including: the promoter CGGGG 
insertion/deletion, which strengthens the binding site for 
the Sp1 transcription factor and thus aﬀ  ects the expres-
sion of the gene [74]; the SNP rs2004640, which creates 
an alternative 5´-donor splice site leading to the splicing 
of the alternative 5´-UTR exon 1B; the in-frame 
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Page 2 of 16Table 1. Genetic associations involving molecules of the type I interferon pathway
   Associated    Functional  eff  ect
Chromosome Gene  polymorphisms  Disease/trait  (if  demonstrated)  References
Genes with strong evidence of association and/or good replication studies 
1q21-24  FCGR2A  rs1801274 (R131H)  SLE, PAPS  R131 has lower affi   nity to IgG2, which may aff  ect the  [85,105,106]
        clearance of immune complexes
2q24.3  IFIH1 (MDA-5)  rs1990760 (T946A),   T1D, RA,     [183-186]
    rs3747517 (R843H)  MS, GD
    rs35337543 (G>C),   T1D  E627X and I923V are loss of function mutations.   [10,187]
    rs35667974 (I923V),     E627X results in deletion of the C-terminal region 
    rs35744605 (E627X),     necessary for dsRNA binding activity. I923V alters a 
    rs35732034 (G>A)    conserved residue, which might impair the signalling 
7q32  IRF5  CGGGG promoter insertion/  RA, T1D, SLE,   CGGGG and rs10954213 risk alleles enhance  [68,70,72,74,
    deletion, rs2004640, exon 6   IBD, pSS  expression levels of IRF5. SNP rs2004640 and exon 6  75,78,188]
    insertion/deletion rs10954213    insertion/deletion determine alternative splice isoforms 
2q32.2  STAT4  rs7574865, rs7568275,   RA, SLE, pSS,   Risk haplotype associated with high levels of expression  [144,146-
    rs3821236, rs10168266  psoriasis, PAPS  and greater sensitivity to IFNα  150,164,169,
         189,190]
9p13.2  TYK2  rs2304256, rs12720270,   SLE, MS  rs12720270 located in a intron/exon boundary might  [69,141-143,
    rs34536443    be involved in alternative splicing  149]
8p23-p22  BLK  rs13277113, rs2736340  SLE, PAPS  Promoter SNPs associated with reduced expression   [145,149,169]
       of  BLK
4q24  BANK1  rs10516487 (R61H), rs17266594,   SLE, RA  rs17266594 determines the transcription ratio  [149,166,171-173]
    rs3733197 (A383T)     between the full-length and delta 2 isoforms
Good evidence      
1q21-24  FCGR3B  NA1/NA2, CNV of the   SLE, mPA, WG  NA1-homozygous has stronger FcγR-mediated  [107]
    whole gene    phagocytic response. Increased risk for SLE with 
        <2 gene copies 
4q21-q25  SPP1  rs1126616, rs1126772,     3´-UTR polymorphisms associated with high  [130,131,136,137]
    rs9138, rs7687316    amounts of ostepontin and IFNα in sera of 
        patients with SLE. Evidence of rs9138–gender 
       interaction
5q32-q33.1  TNIP1  rs10036748, rs7708392  SLE  No functional polymorphism yet identifi  ed. TNIP1   [86,136,191]
        is the A20-binding inhibitor of NF-κB activation and 
        together with A-20 serves as brake for interferon 
        production induced via TLR
   rs17728338  Psoriasis   
16p13.3  DNASEI   V89M, K5X, 46_72 deletion,   SLE, AITD  V89M and K5X are associated with lower enzymatic  [179,192-194]
    rs179982-rs1030874-rs1059857     activity. Haplotype rs179982-rs1030874-rs1059857 
    haplotype,.    defi  nes isoforms of DNaseI  
3p21.31  TREX1   R114H, 158V, P212fs, G227S,   SLE, pSS  R114H associated with decreased exonuclease  [180,181]
 (DNASEIII)  R240S, A247, P272fs, P290L,     activity. Frameshift mutations D272fs and P212fs alter
    Y305C, G306A    subcellular localization of the protein 
Good evidence but more replication studies are required   
2p13-p12  REL  rs13031237, rs13017599  RA    [93]
3q13.11  CBLB  F328L T1D    [195]
1q21-24  FCGR3A  rs396991, V176F  Lupus nephritis    [105]
1q21-24  FCGR2B  I232T SLE    [105]
8q13  LYN  rs6983130 SLE    [85,176]
5q31.1  IRF1  rs2070721   MS, JIA    [161,196]
2q.36  IRS1  rs1801278, G972R   T1D     [197]
16q24.1  IRF8  rs17445836 MS    [90]
2q32.2  STAT1  rs2066802, rs1547550  MS    [161]
11q24.2  TIRAP  rs8177374, S180L   SLE, IBD    [198,199]
Continued overleaf
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Page 3 of 16inser  tion/deletion of the repetitive sequence in exon 6, 
which makes two families of the alternative IRF5 
transcripts [75] (the exon 6 insertion/deletion is located 
in the putative PEST domain of the protein, but its 
function at present remains unknown); and, ﬁ  nally, the 
SNP rs10954213, which alters the polyadenylation signal. 
Th   e presence of the G allele results in a longer 3´-UTR 
with two AU-rich elements rendering the transcript for 
rapid degradation, while the A allele generates mRNA 
with a short and stable 3´-UTR [76]. It has been shown 
that only the promoter insertion/deletion and the poly(A) 
SNP alter the gene expression levels [77]. Th   e level of the 
alternative transcripts caused by the T allele of rs2004640 
is very low, and it encodes for essentially the same protein 
isoforms as the transcripts with the major exon 1A.
A high-risk IRF5 haplotype has been deﬁ  ned and is 
predicted to give rise to transcripts expressing exon 1B 
isoforms (rs2004640-T), to carry the exon 6 insertion, 
and to be overexpressed because of the poly(A) variant 
(rs10954213-A) [78]. Th   e fourth variant is rs20710197(C), 
or its proxy rs10488631, and is an excellent predictor or 
tag of the risk haplotype in Caucasians and Hispanics 
[68,77-80]. Niewold and colleagues demonstrated that 
this well-deﬁ  ned SLE risk haplotype is associated with 
higher serum IFNα activity in patients with SLE [79]. 
Moreover, the diﬀ  erential eﬀ  ect of the IRF5 genotype on 
serum IFNα activity is more pronounced in SLE patients 
positive for either anti-RNA-binding proteins (anti-RNP) 
or anti-dsDNA autoantibodies [79]. Th  is eﬀ  ect suggests 
the possibility of a tight link between autoantibodies and 
IRF5; that is, autoantibodies containing residual nucleic 
acids may enhance TLR-mediated signalling in indivi-
duals with a given risk genotype, and hence high expres-
sion of IRF5, and may predispose them to a greater pro-
duction of IFNα.
Th   e strong genetic link of IRF5 with various autoimmune 
diseases across many populations may be due to the place 
IRF5 has in the signalling cascades. It lies downstream in 
the signalling path of many diﬀ   erent receptors (TLR4, 
TLR7/8, TLR9), and thus can respond to diverse pathogens 
[81-83]. Furthermore, the gene is expressed in pDCs, 
monocytes and B cells, and its enhanced function may 
cause overexpression of IFNα/β and the proinﬂ  ammatory 
cytokines TNFα, IL-6 and IL-12 in these cells [83]. Many 
other genes, including the transcription factors signal 
transducer and activator of transcription (STAT) 1 and 
STAT3, which mediate the interferon-signal  ling pathway, 
are also regulated by IRF5. Over  expression of IRF5 may 
lead to accelerated apop  tosis, contributing to the increased 
burden on the immune clearance system [65,75]. Th  e 
enhanced function of the IRF5 gene caused by the high-
risk allelic variants may therefore lead to systemic eﬀ  ects 
of the immune system.
In this regard it is interesting to mention that the 
frequency of the IRF5 risk haplotype among healthy 
Mexicans is higher compared with that among Europeans 
(20% vs. 9%) and is even higher in Mazateco Mexican 
Indians (31%) [80]. As for the lupus patients, the diﬀ  er-
ence is even more striking – with 20% of the homozygous 
haplotype in Mexican SLE patients as compared with 
3.3% in European SLE patients. It is tempting to speculate 
that this phenomenon originated from the positive 
Table 1. Continued
   Associated    Functional  eff  ect
Chromosome Gene  polymorphisms  Disease/trait  (if  demonstrated)  References
Good evidence but more replication studies are required   
6q21  ATG5  rs6568431 SLE    [85]
Xq28  IRAK1  rs2239673-rs763737- SLE   [200]
   rs5945174-rs7061789  GGGG 
   haplotype
Inconsistent replication       
9q32-q33  TLR4  rs4986790 (G299D)   RA, GCA    [201,202]
9p22  IFNA gene cluster  SLE,  MS    [203,204]
21q22.11  IFNAR cluster  IFNAR1:18417, IFNAR2: 11876  MS    [205]
4q24  NFKB1  –94 ATTG insertion/deletion,   T1D, UC, GD    [99,101]
   CA  microsatellite
3p21.3  TLR9  +1174 A>G  SLE    [206]
17q21  STAT3  rs744166, rs12948909  CD    [162]
19q13.3-q13.4  IRF3  rs2304204, rs2304206  SLE    [88]
Alleles associated with increased risk to develop the disease are underlined (alleles over-represented in patients). SLE, systemic lupus erythematosus; PAPS, primary 
anti-phospholipid syndrome; T1D, type 1 diabetes; RA, rheumatoid arthritis; MS, multiple sclerosis; GD, Graves’ disease; IBD, infl  ammatory bowel disease; pSS, primary 
Sjögren’s syndrome; mPA, microscopic polyangiitis; WG, Wegener’s granulomatosis; AITD, autoimmune thyroid diseases; JIA, juvenile idiopathic arthritis; GCA, giant-
cell arteritis; UC, ulcerative colitis; CD, Crohn’s disease.
Delgado-Vega et al. Arthritis Research & Therapy 2010, 12(Suppl 1):S2 
http://arthritis-research.com/content/12/S1/S2
Page 4 of 16Figure 1. Pathways leading to the type I interferon production. Among the family of Toll-like receptors (TLRs), TLR3, TLR4, TLR7/8 and TLR9 are 
known to induce production of type I interferons in various cells. Surface TLR4 recognizes lipopolysaccharides (LPS) from bacterial cell walls and 
trasmit the signal downstream via MyD88-dependent or MyD88-independent pathways resulting in phosphorylation, dimerization and nuclear 
translocation of IRF5 and IRF3, and activation of NF-κB and mitogen-activated protein kinase (MAPK) pathways. Intracellular TLR3, TLR7/8 and TLR9 
residing in the endosomes are activated by viral double-stranded (ds)RNA, single-stranded RNA and unmethylated dsDNA, respectively. TLR3 
signals via adaptor TRIF and activates IRF3, NF-κB and MAPK pathways. TLR7/8 and TLR9 transmit the signal via the adaptor molecule MyD88. The 
intracellular form of osteopontin 1 (SPP1) binds to MyD88 upon ligation of TLR9 with unmethylated CpG oligonucleotides and promotes induction 
of IFNα genes in mouse plasmacytoid dendritic cells (pDCs). TLR7 and TLR9 are the only receptors expressed in pDCs, while other cells contain 
other TLRs as well. Detection of nucleic acids by TLRs in intracellular endosomes prevents immune responses to the host self-DNA. Normally, nucleic 
acids released by dying necrotic or apoptotic cells undergoing rapid degradation by nucleases, DNaseI and DNaseIII (TREX1), while bacterial or viral 
nucleic acids are protected by the cell wall or viral capsid and could be detected by TLRs only after penetrating the cell. Breach of tolerance to self-
DNA and activation of pDCs could happen if self-DNA remains undegraded due to defective function of the nucleases and meet endosomal TLR9. 
Cationic antimicrobial peptide LL37 and high-mobility group box 1 protein (HMGB1) released by damaged or infected cells, mainly keratinocytes 
and neutrophils, bind DNA making it resistant to degradation and facilitate endocytosis of DNA through the lipid rafts and receptor for advanced 
glycation end-products (RAGE), delivering it to TLR9. DNA/DNA-protein aggregates could be recognized by anti-DNA/anti-RNA-binding proteins 
(anti-RNP) antibodies produced by the autoreactive B cells. Binding of these immune complexes to the low-affi   nity Fcγ receptors II leads to their 
internalization and translocation to the endosomes containing TLR9. Viral DNAs residing in the cytoplasm could be detected by two cytoplasmic 
DNA sensors, DNA-dependent activator of interferon regulatory factors (DAI) and absent in melanoma 2 (AIM2), which trigger induction of type I 
interferon genes through TBK1-mediated and IRF3-mediated signalling. AIM2 also activates caspases 1 and 3 by recruiting adaptor ASC (apoptosis-
associated speck-like protein containing a CARD) and forming an infl  ammasome that promotes release of IL-1β and IL-18. Two RNA helicases, 
retinoic acid-inducible gene 1 (RIG-1) and melanoma diff  erentiation-associated gene 5 (MDA-5), detect viral RNAs in the cytoplasm. Activated RIG-1 
and MDA-5 interact with adaptor protein MAVS anchored by its C-terminal domain to a mitochondrion. This interaction triggers signalling through 
TRAF3 and TRAF6 adaptors and results in activation of IRF3, IRF7 and NF-κB pathway. Autophagosomes can engulf the replicating viral RNAs and, 
after fusion with endosomes, present it to the TLR7/8. Viral RNAs can induce a common antiviral defence mechanism aimed at blocking viral 
replication through total inhibition of cellular transcription and translation. Thus, dsRNAs activate 2´,5´-oligoadenylate synthase (OAS) producing 
2´,5´-oligoadenylates, which in turn activate the latent nuclease RNase L, resulting in the degradation of all cytoplasmic RNAs. Another pathway 
targets protein synthesis machinery by protein kinase dsRNA-dependent serine–threonine kinase (PKR), which inactivates the alpha subunit of 
initiation factor eIF2, resulting in rapid inhibition of protein translation. The latter two pathways may induce apoptosis of the infected cell. Yellow 
stars, genes with strong evidence for association with autoimmune diseases; black stars, genes with inconsistent association. ISG, interferon 
stimulated genes; PI3K, phosphoinositide 3-kinase.
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alleles, and hence high expression of IRF5 and inter-
ferons, which gave them survival advantages against 
certain viral infections brought from the Old World. At 
the same time, the side eﬀ  ect of this survival might be 
leading to a more severe SLE in Mexican patients, 
characterized by the earlier onset and frequent renal and 
other organ damage [84].
Remarkably, neither IRF3 nor IRF7 seem to be reliably 
associated with autoimmunity. Although a SNP (rs4963128) 
in  PHRF1 (previously known as KIAA1542)  has been 
convincingly associated with SLE [85,86], and this 
association is believed to be due to linkage disequilibrium 
(LD) with IRF7, no study has yet directly tested IRF7. Th  e 
PHRF1  and IRF7 genes are localized on chromosome 
11p15 in a tail-to-tail mode. Th   e haplotype structure of 
the HapMap-CEU population (data Release 27) [87] 
shows that both loci are located within the same haplo-
type block together with the mucin-like protocadherin 
MUPCDH. Th  e  associated  PHRF1 variant is 23 kb down-
stream of IRF7 and is in rather moderate LD with two 
SNPs in IRF7: rs12805435 (r2 = 0.475) and rs10902178 
(r2 = 0.475). Th   us, even though IRF7 is the most plausible 
candidate in this region given its function in IFNα 
production, its role as a susceptibility gene for SLE 
remains to be veriﬁ  ed.
A promoter polymorphism in the IRF3 gene conferring 
higher expression of IRF3 was associated with SLE in one 
Japanese study [88]; however, the association was not 
corroborated on a larger set of Spanish patients [89]. Of 
note, IRF3 is constitutively expressed at high levels in all 
cells, while low levels of IRF7 are present in cells of lym-
phoid origin. Th  is contrasts to an even more restricted 
pattern of expression of the IRF5 gene, as mentioned 
above.
Th   e SNP rs17445836 located 61 kb downstream of the 
IRF8 gene has been recently associated with multiple 
sclerosis [90]. Although the authors concluded that the 
most likely susceptibility gene was IRF8, the block where 
the SNP is located is separated from IRF8 by three 
recombination hot spots [90]. Interestingly, the presence 
of the risk allele G of rs17445836 was positively correlated 
with expression levels of the IRF7 and IFIH1 genes, but 
not with IRF8 itself or interferon genes.
Th   e transcription factor NF-κB is a central regulator of 
immune responses and inﬂ   ammation, and is present 
virtually in all cell types. It is composed of homodimers 
or heterodimers formed by the members of the NF-κB 
family, which include RelA (p65), RelB, c-Rel, NF-κB1 
(p50) and NF-κB2 (p52) [91]. Single and double knockout 
mouse models for these genes display survival and 
phenotypic diﬀ   erences, suggesting that, despite some 
overlapping functions, they all have unique roles in the 
immune system (reviewed in [92]). Recently, the gene 
coding for c-Rel (REL) was identiﬁ  ed as a susceptibility 
locus for RA [93]. c-Rel expression is restricted to 
haemato  poietic cells and lymphocytes, and mainly to T 
cells and B cells. In contrast, RelA, NF-κB1 and NF-κB2 
are widely expressed in various cell types and constitute 
the major classic NF-κB factor, residing in its inactive 
form in the cytoplasm. Stimulation of cells activates 
NF-κB, which translocates into the nucleus and induces 
the expression of a great number of genes. Interestingly, 
constitutively active nuclear heterodimer p50/c-Rel is 
found in mature B cells also co-expressing the cyto-
plasmic heterodimer p50/p65, suggesting a speciﬁ  c func-
tion for c-Rel in B-cell stimulation [94]. Mice deﬁ  cient for 
c-Rel develop normally and display only unresponsiveness 
of B cells and T cells to certain mitogenic stimuli [95]. B 
cells lacking c-Rel show increased sensitivity to B-cell 
receptor-mediated apoptotic signals [96]. c-Rel is 
indispensable for expression of IL-12 and IL-23 subunits 
in mouse dendritic cells [97,98].
With exception for one more member of the family, 
NF-κB1 – which has been inconsistently associated with 
genetic susceptibility to some of the autoimmune 
diseases [99-101] – no other factors were found to be 
linked with autoimmunity. Remarkably, NF-κB1 knockout 
mice – unlike knockout mice for RelA, RelB, or NF-κB2 – 
have only minor defects in lymphocyte activation, and 
particularly in B-cell responses [102].
Genes involved in clearance of immune complexes – 
Fc gamma receptors
SLE patients display an increased rate of apoptosis of 
peripheral mononuclear cells and decreased clearance of 
the circulating immune complexes (ICs), which together 
may lead to the accumulation of high titres of ICs and 
cause organ damage [103,104]. Th   e Fc gamma receptors 
(FcγR) are low-aﬃ   nity receptors for the Fc portion of IgG 
and play a critical role in the clearance of ICs. Several 
polymorphisms for FcγRIIa, FcγRIIb, FcγRIIIa and 
FcγRIIIb genes located in a tight cluster on chromosome 
1q23 have been associated with SLE, lupus nephritis and 
primary anti-phospholipid syndrome [85,105-107]. Th  e 
most consistent association, replicated in various popu-
lations of diverse ethnic groups, is the missense variation 
of  FCGR2A (Arg131His) located in the ligand binding 
domain of the receptor [106]. Arginine coded by the 
susceptibility allele signiﬁ   cantly reduces the aﬃ   nity  of 
binding to circulating IgG2. Th  is, in turn, results in 
impaired FcγR-mediated phagocytosis and poor clearance 
of ICs.
Receptor ligation leads to the activation and maturation 
of dendritic cells and enhances their ability to stimulate 
T cells via cross-presentation of antigens and enhanced 
secretion of inﬂ  ammatory cytokines. Interestingly, pDCs 
express FcγRIIa containing the activation ITAM domain, 
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It was shown also that ligation of FcγRIIa triggers IFNα 
production by pDCs [108]. In this regard, it is unclear 
how to reconcile the stimulatory function of the receptor 
on the interferon genes and the association with the risk 
allele that impairs this function. It might be that the 
primary eﬀ   ect is cell-type speciﬁ   c and unrelated to 
interferon production, and is rather the result of impaired 
internalization of immune complexes. Since FcγRIIa is 
present also on the surface of neutrophils, monocytes, 
macrophages, and platelets, its dysfunction on these cells 
could yield to the greater amount of circulating ICs. It 
has also been suggested that FcγRIIa might have dual 
ability to deliver both activating and inhibiting signals 
depending on the cell type and the milieu [108]. Another 
as yet unproven hypothesis suggests that variations in 
FcγRIIa, FcγRIIb and FcγRIIIa aﬀ  ect risk in a compound 
heterozygote fashion, and cause disbalance in stimulatory 
and inhibitory signals [109].
Other genes required for type I interferon production
A new function in the TLR9-mediated induction of IFNα 
genes in pDCs has been recently described for the intra-
cellular form of murine osteopontin 1 (early T-lympho-
cyte activation protein 1, Eta-1, or SPP1) [110,111]. Th  e 
majority of osteopontin 1 is secreted from activated 
T cells, NK cells and dendritic cells, and plays a key role 
in bone morphogenesis [112,113]. Its immune functions 
include activation of T cells, T-helper type 1 cell diﬀ  er-
entiation, and activation of B cells and macrophages 
[114-116]. TLR9 activation by CpG-rich DNA causes 
rapid association of intracellular osteopontin with the 
adaptor MyD88 and leads to the induction of interferon 
genes in an IRF7-dependent manner [111]. Although 
these data have been obtained from mouse dendritic 
cells, several lines of evidence suggest the existence of a 
similar pathway in humans. First, elevated levels of serum 
osteopontin were detected before and during relapses of 
diﬀ   erent auto  immune diseases, including multiple 
sclerosis, SLE, RA and inﬂammatory bowel disease, in 
humans and their relevant mouse models [117-128]. 
Second, polymor  phisms associated with autoimmunity 
and high levels of osteopontin were found in both species 
[119,129-133]. In mice IRF7 plays a major role in 
induction of IFNα/β genes in pDCs, while in humans 
IRF5 is more important than IRF7 – although both 
factors are able to induce type I interferons [65,82,83, 
134,135]. Whether or not human osteopontin 1 is also 
able to activate IRF5 in human pDCs is unknown at 
present.
Interestingly, polymorphisms located in the 3´-UTR 
region (rs1126616T and rs9138C) of the human SPP1 
gene show much stronger association with SLE in men 
than in women [136,137]. Th  e  haplotype 
rs1126616T-rs1126772A-rs9138C, however, is also 
associated with SLE in general [136]. Moreover, rs9138C 
is associated with high amounts of serum osteopontin 
and IFNα in men and young women [137]. Of note, 
gender-related diﬀ   erences in SPP1 expression were 
observed also in rats [138,139]. Bioinformatic analysis of 
the associated SNPs located in the 3´-UTR suggested 
that they might disrupt micro-RNA target sites, and thus 
aﬀ  ect the gene expression [136]. More detailed analysis is 
required, however, to verify this hypothesis. SNPs located 
in the 5´ region of the gene (rs11730582 and rs28357094) 
were associated with anti-RNP antibodies in African-
Ameri  cans, while in European-Americans and Hispanic-
Americans only a nonsigniﬁ  cant trend toward association 
was observed [137]. Th  e study was suggested to be 
under  powered because of the much lower frequency of 
individuals carrying anti-RNP antibodies in these two 
populations.
Genetic linkages to the signalling pathways 
induced by type I interferons
Type I interferons bind to a common ubiquitous receptor 
composed of the two chains IFNA-R1 and IFNA-R2, 
coded by two distinct genes located on chromosome 
21q22 [140]. Th  e IFNA-R2 subunit is believed to have 
generally higher aﬃ   nity to interferons, although it has 
been reported that various types and subtypes of type I 
interferon have diﬀ  erent aﬃ   nities and kinetics of binding 
to the receptor subunits, which may lead to diﬀ  erential 
downstream signalling [2]. Th  e antiviral activity of 
interferons correlates with their binding aﬃ   nities  to 
IFNA-R2, while anti-proliferative activity depends rather 
on the aﬃ   nity to IFNA-R1 [2]. Ligand binding causes 
receptor dimerization and phosphorylation of two asso-
ciated protein tyrosine kinases, Tyk2 and Jak1, followed 
by direct activation of multiple redundant signalling 
pathways. Th  e biological activities of interferons are 
context speciﬁ  c and depend upon the interferon subtype, 
the cell type (pDCs, T cells, B cells, NK cells, cytotoxic 
lymphocytes, other tissue-speciﬁ   c cells), concomitant 
signals such as cytokines present in the surrounding 
environment, and activation of other co-receptors (B-cell 
receptor/T-cell receptor, and so forth). Alternative 
splicing of IFNA-R2 produces two transmembrane 
isoforms diﬀ  ering in the cytoplasmic domains, and one 
soluble isoform may contribute to the diﬀ  erential 
signalling as well. Th  ree major pathways transmit the 
signal from IFNA-R: the Jak/STAT, mitogen-activated 
protein kinase and phosphoinositide 3-kinase pathways 
(summarized in Figure  2). All of the pathways may 
overlap to some extent. Downstream signalling results in 
the induction of hundreds of genes necessary for antiviral 
defence, which together establish the speciﬁ  c pattern of 
genes – termed the interferon signature.
Delgado-Vega et al. Arthritis Research & Therapy 2010, 12(Suppl 1):S2 
http://arthritis-research.com/content/12/S1/S2
Page 7 of 16Associations with molecules providing direct downstream 
signalling from the interferon receptor
Th  e  TYK2 gene was reported as associated with SLE in 
the same study that revealed the association for IRF5 
[69]. Unlike IRF5, the ﬁ   rst replication attempts where 
contro  versial [141], but to date many more studies have 
conﬁ  rmed TYK2 as a susceptibility locus for SLE and it 
has also been incriminated in multiple sclerosis 
suscep  tibility [86,142,143]. Furthermore, a recent study 
in Finnish patients with SLE found signiﬁ  cant evidence 
for interaction between rs2304256 in TYK2  and 
rs10954213 in IRF5 [142]. No functional polymorphism 
in TYK2, how  ever, has yet been described.
Among the STAT genes, only STAT4 is reported to be 
associated with several autoimmune disorders in 
Caucasian populations [144-150], Hispanic populations 
Figure 2. Pathways activated by type I interferons. Engagement of interferons by interferon receptors activates Jak-signal transducer and 
activator of transcription (STAT), mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signalling pathways. Jak1-Tyk2-
mediated phosphorylation preferentially activates STAT1 and STAT2, which make either homodimers that induce genes with IFNγ-activated site 
(GAS)-dependent promoters, or heterodimers that bind IRF9 and regulate expression of the genes with interferon-stimulated response elements 
(ISRE). Other STAT molecules have a more restricted pattern of expression and could be activated by interferons in a cell-specifi  c manner. p38 
MAPK is activated in a series of signalling events initiated by IFNα/β and is necessary for induction of genes with both ISRE and GAS-dependent 
promoters. Type I interferons induce phosphorylation of a number of adaptor proteins, including members of the insulin receptor substrates (IRS1, 
IRS2, IRS3, and IRS4), growth-factor-receptor-bound protein 2 (GRB2)-associated binding protein 1 and 2 (GAB1 and GAB2) and members of the 
CRK family (CRKL, and CRK I and CRK II). Phosphorylated CRKL binds through its SH2 domain with STAT5 and activates GAS-dependent genes. Other 
tyrosine kinase substrates, such as Casitas B-lineage lymphoma (CBL), CBL-b, p130cas and paxillin, also bind to CRKL through the SH2 domain. The 
guanine-exchange factor C3G interacts with the SH3 domain of CRKL and activates small GTPase RAP 1, which participates in the regulation of 
cell growth, proliferation and diff  erentiation. Activated IRS adaptors provide binding sites for the p85 regulatory subunit of PI3K, which results in 
the activation of the catalytic function of the p110 subunit. PI3K is known to activate a number of downstream signalling molecules aff  ecting all 
aspects of cell biology. Thus, tissue-specifi  c isoforms of protein kinase C (PKC) family, PKCδ, PKCε, PKCθ and PKCη, phosphorylate serine residues in 
the STAT factors and p38 MAPK. Pharmacological inhibitors that block the activity of distinct PKCs aff  ect the expression of the interferon-responsive 
genes. The PI3K-AKT signalling cascade mediates survival signals in a cell-type-restricted manner, inducing both anti-apoptopic and pro-apoptotic 
pathways, and translation of cap-dependent transcripts. Type I interferons activate two members of Src family of kinases, Fyn in T cells and Lyn in 
B cells. Lyn kinase in its turn phosphorylates B-cell-specifi  c adaptor protein BANK1, facilitating formation of a complex between BANK1, BLK kinase 
and IP3 receptor 2 (IP3R2). Yellow stars, genes with strong evidence for association with autoimmune diseases; black stars, genes with inconsistent 
association. ISG, interferon stimulated genes; OAS, 2´,5´-oligoadenylate synthase; PKR, protein kinase dsRNA-dependent serine–threonine kinase.
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Page 8 of 16[146,151] and Asian populations [152-155]. STAT4 is 
expressed mainly in T cells, NK cells, activated mono-
cytes and dendritic cells [156], where it resides in the 
cytoplasm in its inactive form. Upon cell activation with 
IL-12, IL-23 or IFNα/β, STAT4 becomes phosphorylated 
by tyrosine kinases, forms homodimers and translocates 
into the nucleus, where it induces expression of IFNγ 
[157]. STAT4 is essential for diﬀ  erentiation of naïve CD4+ 
T cells into T-helper type 1 cells [158-160]. STAT4 maps 
to human chromosome 2q32.2 next to STAT1 in a head-
to-tail mode with moderate LD between them, which 
could account for the weak association signal for STAT1 
detected in multiple sclerosis [161] and SLE [144]. STAT3 
was recently reported to be associated with Crohn’s 
disease [162].
Currently, the strongest and more replicated associa-
tion signal within STAT4 is located in the third intron of 
the gene [144,147,148,152]. We reported an independent 
association with a haplotype covering the region from 
exons 6 to 16, which represents the strongest eﬀ  ect 
within  STAT4 for Argentineans and Spanish patients 
with SLE, while the intron 3 variants have the strongest 
eﬀ  ect in Italians and Germans [144]. Th  is population-
speciﬁ  c haplotype eﬀ  ect was independently conﬁ  rmed by 
a study in SLE patients of Hispanic and African-
American origin. Th  is study revealed diﬀ  erences in the 
haplotype structure of STAT4 between populations: the 
LD between the two associated haplotype blocks (the 
intron 3 haplotype and the exon 6 to 16 haplotype) is 
lower in non-European populations compared with 
European-derived populations [146]. Th  e frequency of 
this haplotype is much higher in Hispanics compared 
with Europeans [144,146]. It has been demonstrated that 
the intron 3 association is particularly stronger in 
patients with anti-dsDNA autoantibodies, nephritis and 
early disease onset [148,152,163]. Th  e reported allelic 
heterogeneity of STAT4 might thus either be reﬂ  ecting 
true population diﬀ  erences or these two haplotypes could 
be important in diﬀ   erent clinical and/or serological 
subsets of patients.
Th  e  STAT4 haplotype risk correlates with higher levels 
of  STAT4 expression, which seems to be cell speciﬁ  c 
[144,148]. Besides, the tissue-speciﬁ  c alternative promo-
ters identiﬁ  ed for STAT4 suggest a more complex regula-
tion of the gene, which poses an additional obstacle in 
the search for the causative variants and their eﬀ  ects. 
One recent study reported a striking correlation between 
the risk allele of SNP rs7574865 and increased expression 
of interferon-induced genes in the absence of high 
amounts of interferon [164]. Th  is increased expression 
may lead to a lower threshold for disease initiation. 
Moreover, the disease-associated alleles for IRF5 and 
STAT4 variants have an additive eﬀ  ect on the risk for SLE 
[144,148]. Interestingly, STAT4 expression – unlike any 
other STAT genes – is restricted mainly to T cells and 
NK cells, and in this respect it is reminiscent of the very 
limited expression pattern for IRF5 [165]. Further 
re-sequencing of STAT4 might be necessary in order to 
identify the true functional variants.
Associations with genes modulated by type I interferons
Although some genes and their products may not directly 
participate in the signalling from the interferon type I 
receptors, they still may be regulated by interferons and 
comprise a large group of genes included in the interferon 
signature pattern. We will focus on two genes/proteins 
modulated by type I interferon, Src-family tyrosine kinase 
BLK and adaptor protein BANK1, because they are 
conﬁ   rmed SLE susceptibility loci as identiﬁ  ed  by 
genome-wide association studies, both are speciﬁ  c for B 
cells and their expression in B cells is modulated by type I 
interferons [145,166]. To date, the association of BLK 
with SLE has been replicated in European [149], Japanese 
[167] and Chinese [155] popu  lations, and it has also been 
implicated in RA [168] and primary anti-phospholipid 
syndrome [169]. Th  e risk allele of the SNP rs13277113, 
located in the promoter region of BLK, is negatively 
correlated with the levels of BLK. It has also been shown 
that treatment with IFNα rapidly downregulates 
expression of BLK  and, moreover, its expression is 
negatively regulated by infection with Epstein–Barr virus, 
which has been suggested as one of the environmental 
triggers for autoimmune diseases [170]. Low levels of 
BLK, determined by the risk allele, exposure to high 
amounts of interferon, and infection with Epstein–Barr 
virus altogether might therefore exert a cumulative eﬀ  ect 
on risk through negative regulation of BLK in B cells.
BANK1 association was identiﬁ   ed in Scandinavian 
patients with SLE [166] and further replicated in Euro  pean 
Americans [86,149,171] and Chinese popu  lations [172]. It 
has also been incriminated in RA, although with a less 
strong eﬀ  ect size [173]. Th   ree disease-associated variants 
have been described: rs10516487 (R61H) located in exon 
2; rs17266594, which is in strong LD with rs10516487 (r2 = 
0.90) and is located in intron 2, where it alters the branch-
point site; and an independent signal in exon 7 coding for 
an ankyrin domain (rs3733197, A383T) [166]. Th  e 
variation at the branch-point site alters the eﬃ   ciency of 
splicing of exon 2. Th   e risk allele of rs17266594 correlates 
with high levels of the full-length isoform and low levels of 
the alternative isoform lacking the entire exon 2, which 
codes for a putative binding domain for inositol 
1,4,5-triphosphate receptor type 2 (IP3R2), known to 
associate with BANK1 upon B-cell activation [174].
We have observed that polymorphisms of BANK1, BLK 
and  ITPR2  genes display statistical genetic interaction, 
increasing substantially the risk to develop SLE 
(Castillejo-Lopez C, Delgado-Vega AM, Wojcik J, et al., 
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Page 9 of 16submitted data) [175]. Interestingly, LYN – another 
B-cell-speciﬁ   c tyrosine kinase recently associated with 
SLE [85,176] – may activate BANK1 through 
phosphorylation, leading to further stimulation of its 
interaction with IP3R2. Reduced levels of LYN were also 
detected in B cells of lupus patients [177]. Of note, 
expression of BANK1 in B cells is upregulated by type I 
interferons and, together with decreased levels of either 
of the kinases LYN or BLK, may signiﬁ  cantly distort the 
signalling and lead to increased production of 
autoantibodies – although the precise role for the adaptor 
protein BANK1 in B cells is awaiting elucidation.
Conclusion
Autoimmune diseases are caused by the breakdown of 
self-tolerance and are characterized by persistent activa-
tion of immune cells, leading to histopathological damage 
in the absence of an ongoing infection or other 
discernible cause [178]. Th  ese diseases have complex 
genetic heritability with many genes giving modest 
contri  butions to the disease initiation and perpetuation. 
Given the role of type I interferons in autoimmunity, the 
associated genetic variants that have been reviewed in 
the present article are believed to lead either to the 
excessive production of interferons and further ampliﬁ  -
cation of the deleterious interferon-mediated signalling, 
or to impaired negative regulation of the interferon 
pathways, or to abnormal response to interferons caused 
by the increased sensitivity of cells. Remarkably, the most 
strongly asso  ciated genes, such as IRF5 and STAT4, are 
not only replicated in many populations, but also 
predispose to various autoimmune diseases. On the other 
hand, genes with weaker signals are rather associated 
with speciﬁ  c clinical manifestations; that is, they aﬀ  ect 
only speciﬁ  c subsets of patients with particular disease, 
and as such may be considered disease modiﬁ  ers rather 
than true susceptibility genes.
Based on the two most studied examples – IRF5 and 
STAT4 – it is tempting to speculate that common shared 
genes are located in the major knots of the signalling 
cascades. Th  e current lack of data on association of a 
particular gene, already found to be associated with a 
speciﬁ   c disease, with other autoimmune diseases, 
however, does not mean a lack of association per se. 
Given the generally low prevalence of autoimmune 
diseases, it is often a challenging task to collect a large 
enough number of patients with another autoimmune 
disease from the same population. It is possible also that 
complex epistatic interactions hinder genetic associa-
tions, and thus will require more detailed analysis of an 
individual’s genotypes for various genes.
Another complication was recently highlighted by the 
ﬁ  nding that rare mutations or copy number variations 
may lead to the development of autoimmune diseases. 
Rare nonsense mutations have been detected in the 
DNASE1 gene in two Japanese SLE patients [179]. A 
number of rare mutations associated with SLE and 
Sjogren’s syndrome were identiﬁ  ed recently for another 
nuclease,  TREX1 [180,181]. Likewise, protection against 
type 1 diabetes was associated with four rare variants in 
the IFIH1 gene [10]. Th   is highlights the challenge of gene 
re-sequencing and the importance of projects like the 1000 
genomes [182] in order to ﬁ  nd noncommon variants with 
highly penetrant eﬀ  ects in autoimmune diseases.
Despite the fact that interferons are linked to many 
diseases, the exact role of diﬀ  erent types of interferons in 
various autoimmune diseases may be diﬀ  erent, or even 
opposite. While treatment with recombinant interferons is 
known to ameliorate multiple sclerosis, it triggers the 
development of SLE, type 1 diabetes, psoriasis, inﬂ  am-
matory arthritis and pSS [39,40]. Th  e genes and alleles 
associated with distinct diseases in connection with 
interferon-mediated pathways could therefore obviously 
be diﬀ  erent.
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